These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 20093514)

  • 1. Noninvasive contrast-enhanced US quantitative assessment of tumor microcirculation in a murine model: effect of discontinuing anti-VEGF therapy.
    Guibal A; Taillade L; Mulé S; Comperat E; Badachi Y; Golmard JL; Le Guillou-Buffello D; Rixe O; Bridal SL; Lucidarme O
    Radiology; 2010 Feb; 254(2):420-9. PubMed ID: 20093514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Can the effect of antiangiogenic treatments be monitored and quantified noninvasively by using contrast-enhanced US?
    Forsberg F
    Radiology; 2010 Feb; 254(2):317-8. PubMed ID: 20093504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative assessment of tumor blood flow in mice after treatment with different doses of an antiangiogenic agent with contrast-enhanced destruction-replenishment US.
    Zhou JH; Cao LH; Liu JB; Zheng W; Liu M; Luo RZ; Han F; Li AH
    Radiology; 2011 May; 259(2):406-13. PubMed ID: 21292869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy.
    Dickson PV; Hamner JB; Sims TL; Fraga CH; Ng CY; Rajasekeran S; Hagedorn NL; McCarville MB; Stewart CF; Davidoff AM
    Clin Cancer Res; 2007 Jul; 13(13):3942-50. PubMed ID: 17606728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contrast-enhanced ultrasound with perflubutane in the assessment of anti-angiogenic effects: early prediction of the anticancer activity of bevacizumab in a mouse xenografted model.
    Watanabe R; Munemasa T; Matsumura M
    Ultrasound Med Biol; 2015 Sep; 41(9):2497-505. PubMed ID: 26022792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular ultrasound imaging using a targeted contrast agent for assessing early tumor response to antiangiogenic therapy.
    Sorace AG; Saini R; Mahoney M; Hoyt K
    J Ultrasound Med; 2012 Oct; 31(10):1543-50. PubMed ID: 23011617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contrast-enhanced Ultrasound Imaging of Antiangiogenic Tumor Therapy.
    Klotz LV; Clevert DA; Scheckinger S; Strieth S; Eichhorn ME
    Anticancer Res; 2015 May; 35(5):2571-6. PubMed ID: 25964532
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Contrast ultrasound imaging for identification of early responder tumor models to anti-angiogenic therapy.
    Sirsi SR; Flexman ML; Vlachos F; Huang J; Hernandez SL; Kim HK; Johung TB; Gander JW; Reichstein AR; Lampl BS; Wang A; Hielscher AH; Kandel JJ; Yamashiro DJ; Borden MA
    Ultrasound Med Biol; 2012 Jun; 38(6):1019-29. PubMed ID: 22425376
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regions of interest and parameters for the quantitative analysis of contrast-enhanced ultrasound to evaluate the anti-angiogenic effects of bevacizumab.
    Zhang HP; Shi QS; Li F; Liu L; Bai M; Gu JY; Wu Y; Du LF
    Mol Med Rep; 2013 Jul; 8(1):154-60. PubMed ID: 23722237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advanced hepatocellular carcinoma: early evaluation of response to bevacizumab therapy at dynamic contrast-enhanced US with quantification--preliminary results.
    Lassau N; Koscielny S; Chami L; Chebil M; Benatsou B; Roche A; Ducreux M; Malka D; Boige V
    Radiology; 2011 Jan; 258(1):291-300. PubMed ID: 20980447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of bevacizumab, a humanized monoclonal antibody to vascular endothelial growth factor, on peritoneal metastasis of MNK-45P human gastric cancer in mice.
    Ninomiya S; Inomata M; Tajima M; Ali AT; Ueda Y; Shiraishi N; Kitano S
    J Surg Res; 2009 Jun; 154(2):196-202. PubMed ID: 19329124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intra-Animal Comparison between Three-dimensional Molecularly Targeted US and Three-dimensional Dynamic Contrast-enhanced US for Early Antiangiogenic Treatment Assessment in Colon Cancer.
    Wang H; Lutz AM; Hristov D; Tian L; Willmann JK
    Radiology; 2017 Feb; 282(2):443-452. PubMed ID: 27490690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiogenesis inhibitors in a murine neuroblastoma model: quantitative assessment of intratumoral blood flow with contrast-enhanced gray-scale US.
    McCarville MB; Streck CJ; Dickson PV; Li CS; Nathwani AC; Davidoff AM
    Radiology; 2006 Jul; 240(1):73-81. PubMed ID: 16793972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-VEGF antibody therapy induces tumor hypoxia and stanniocalcin 2 expression and potentiates growth of human colon cancer xenografts.
    Miyazaki S; Kikuchi H; Iino I; Uehara T; Setoguchi T; Fujita T; Hiramatsu Y; Ohta M; Kamiya K; Kitagawa K; Kitagawa M; Baba S; Konno H
    Int J Cancer; 2014 Jul; 135(2):295-307. PubMed ID: 24375080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic delivery of the murine equivalent of bevacizumab (avastin), an anti-vascular endothelial growth factor monoclonal antibody, to suppress growth of human tumors in immunodeficient mice.
    Watanabe M; Boyer JL; Hackett NR; Qiu J; Crystal RG
    Hum Gene Ther; 2008 Mar; 19(3):300-10. PubMed ID: 18324912
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibitory effect of bevacizumab on the angiogenesis and growth of retinoblastoma.
    Lee SY; Kim DK; Cho JH; Koh JY; Yoon YH
    Arch Ophthalmol; 2008 Jul; 126(7):953-8. PubMed ID: 18625942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiparametric monitoring of early response to antiangiogenic therapy: a sequential perfusion CT and PET/CT study in a rabbit VX2 tumor model.
    Kim JI; Lee HJ; Kim YJ; Kim KG; Lee KW; Lee JH; Lee HJ; Lee WW
    ScientificWorldJournal; 2014; 2014():701954. PubMed ID: 25383376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contrast ultrasonography: necessity of linear data processing for the quantification of tumor vascularization.
    Peronneau P; Lassau N; Leguerney I; Roche A; Cosgrove D
    Ultraschall Med; 2010 Aug; 31(4):370-8. PubMed ID: 20577941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monitoring Dual VEGF Inhibition in Human Pancreatic Tumor Xenografts With Dynamic Contrast-Enhanced Ultrasound.
    Lamuraglia M; Barrois G; Le Guillou-Buffello D; Santin M; Kerbol A; Comperat E; Coron A; Lucidarme O; Bridal SL
    Technol Cancer Res Treat; 2020; 19():1533033819886896. PubMed ID: 32065066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. VEGFR2-Targeted Contrast-Enhanced Ultrasound to Distinguish between Two Anti-Angiogenic Treatments.
    Payen T; Dizeux A; Baldini C; Le Guillou-Buffello D; Lamuraglia M; Comperat E; Lucidarme O; Bridal SL
    Ultrasound Med Biol; 2015 Aug; 41(8):2202-11. PubMed ID: 25980323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.